Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Medicus Pharma Ltd. (NASDAQ: MDCX ) on Monday announced it will concentrate all future internally sponsored clinical development for its SkinJect asset exclusively on Gorlin syndrome patients presenting with multiple basal cell carcinoma lesions, concluding further development in sporadic nodular basal cell carcinoma.